Phase 2
Lung Transplant
Intervention Type:
Intravenous (IV) Injection
Funder Type:
Organization | University

Drug Details

Amiodarone is a class III antiarrhythmic agent.

Study Purpose

This study will prospectively evaluate the use of an amiodarone releasing hydrogel applied to the pulmonary veins and atria at the time of lung transplantation. This study will include patients undergoing lung transplantation at Jewish Hospital, Louisville KY. The prospective group will be compared to historical controls from the same institution. Investigators will access medical records and database entries for those patients undergoing lung transplantation after January 1st 2005 in order to obtain matched controls for analysis. Informed consent will be obtained from the prospective cohort prior to patient enrollment. This pilot study will be used to obtain preliminary data in order to proceed with a larger randomized control trial.

This drug has no clinical trials actively recruiting patients at this time.